West Pharmaceutical Services, Inc.WSTNYSE
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank72
3Y CAGR-9.3%
5Y CAGR+1.5%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-9.3%/yr
vs +119.3%/yr prior
5Y CAGR
+1.5%/yr
Recent deceleration
Acceleration
-128.6pp
Decelerating
Percentile
P72
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 27.33% |
| Q3 2025 | 11.35% |
| Q2 2025 | 36.86% |
| Q1 2025 | -31.93% |
| Q4 2024 | 5.55% |
| Q3 2024 | 9.15% |
| Q2 2024 | 39.59% |
| Q1 2024 | -50.56% |
| Q4 2023 | 3.91% |
| Q3 2023 | 35.99% |
| Q2 2023 | 22.52% |
| Q1 2023 | -40.16% |
| Q4 2022 | 36.65% |
| Q3 2022 | -2.43% |
| Q2 2022 | 14.48% |
| Q1 2022 | -5.97% |
| Q4 2021 | -15.41% |
| Q3 2021 | 31.65% |
| Q2 2021 | 62.80% |
| Q1 2021 | -40.35% |
| Q4 2020 | 25.38% |
| Q3 2020 | -19.92% |
| Q2 2020 | 159.37% |
| Q1 2020 | -46.33% |
| Q4 2019 | -1.57% |
| Q3 2019 | 2.85% |
| Q2 2019 | 120.80% |
| Q1 2019 | -34.97% |
| Q4 2018 | -17.19% |
| Q3 2018 | 7.80% |
| Q2 2018 | 82.22% |
| Q1 2018 | -44.79% |
| Q4 2017 | 7.52% |
| Q3 2017 | -11.14% |
| Q2 2017 | 312.08% |
| Q1 2017 | -71.17% |
| Q4 2016 | 4.97% |
| Q3 2016 | -10.24% |
| Q2 2016 | 2440.00% |
| Q1 2016 | -95.59% |